{"id":3167,"date":"2014-08-13T06:29:00","date_gmt":"2014-08-13T06:29:00","guid":{"rendered":"https:\/\/www.xvivogroup.com\/us\/mfn_news\/continued-strong-sales-growth-and-sek-73-million-private-placement\/"},"modified":"2014-08-13T06:29:00","modified_gmt":"2014-08-13T06:29:00","slug":"continued-strong-sales-growth-and-sek-73-million-private-placement","status":"publish","type":"mfn_news","link":"https:\/\/www.xvivogroup.com\/us\/pressreleases\/continued-strong-sales-growth-and-sek-73-million-private-placement\/","title":{"rendered":"CONTINUED STRONG SALES GROWTH AND SEK 73 MILLION PRIVATE PLACEMENT"},"content":{"rendered":"

SECOND QUARTER 2014 (APR \u2013 JUN)<\/span><\/strong><\/p>\n

\u2022 Net sales in the quarter amounted to SEK 18.5 (15.8) million, corresponding to an increase of 17 percent in SEK. Sales increased by 15 percent in local currency.<\/span><\/p>\n

\u2022 Operating income before depreciation and amortization (EBITDA) amounted to SEK 1.8 (2.4) million, corresponding to an EBITDA margin of 10 percent.<\/span><\/p>\n

\u2022 Net income amounted to SEK 0.8 (1.7) million, resulting in earnings per share of SEK 0.04 (0.09). <\/span><\/p>\n

\u2022 Cash flow from operating activities was SEK 0.8 (3.9) million.<\/span><\/p>\n

\u2022 STEEN Solution\u2122 and related products accounted for 23 (13) percent of total sales.<\/span><\/p>\n

\u2022 Investment in future sales growth is done through research and development of new indications for STEEN Solution \u2122<\/span><\/p>\n

\u2022 The board of directors resolved to issue new shares through a SEK 73 million private placement directed to a group of qualified Swedish and international investors in order to facilitate a faster build-up of the company\u2019s working capital for the US and European launch of XPS\u2122 and STEEN Solution\u2122 and also for investment in new indications. <\/span><\/p>\n

THE PERIOD 2014 (JAN \u2013 JUN)<\/span><\/strong><\/p>\n

\u2022 Net sales in the period amounted to SEK 36.7 (32.1) million, corresponding to an increase of 14 percent in SEK. Sales increased by 12 percent in local currency.<\/span><\/p>\n

\u2022 Operating income before depreciation and amortization (EBITDA) amounted to SEK 4.9 (6.1) million, corresponding to an EBITDA margin of 13 percent.<\/span><\/p>\n

\u2022 Net income amounted to SEK 2.6 (4.1) million, resulting in earnings per share of SEK 0.13 (0.21). <\/span><\/p>\n

\u2022 Cash flow from operating activities was SEK -2.6 (7.9) million due to changes in trade payables that amounted to SEK -3.3 million and paid taxes that amounted to SEK -3.6 million.<\/span><\/p>\n

\u2022 STEEN Solution\u2122 and related products accounted for 24 (14) percent of total sales.<\/span><\/p>\n

\u2022 The Advisory Panel convened by the FDA voted unanimously, by 10 votes to 0, that the XPS\u2122 System with STEEN Solution\u2122 meets the requirements for HDE (Humanitarian Device Exemption) approval.<\/span><\/p>\n

\u2022 XPS\u2122 (Xvivo Perfusion System) received a CE mark, allowing XPS\u2122 and the accompanying single-use products to be sold in Europe.<\/span><\/p>\n

\u2022 The first lung transplant in Turkey using a lung treated with the STEEN Solution\u2122 method was performed at Sureyyapasa Teaching Hospital.<\/span><\/p>\n

\u2022 The board of directors resolved to issue new shares through a SEK 73 million private placement directed to a group of qualified Swedish and international investors in order to facilitate a faster build-up of the company\u2019s working capital for the US and European launch of XPS\u2122 and STEEN Solution\u2122 and also for investment in new indications. <\/span><\/p>\n

SIGNIFICANT EVENTS AFTER THE END OF THE QUARTER <\/span><\/strong><\/p>\n

\u2022 XVIVO has received market approval from the FDA for STEEN Solution\u2122 and XPS\u2122.<\/span>
<\/span><\/p>\n

\u2022 XVIVO Perfusion\u2019s share warrant program 2014\/2016, offered to employees, was fully subscribed.<\/span><\/p>\n

\u2022 The private placement increased the number of shares and votes in XVIVO Perfusion by 1,950,000 from 19,562,769 to 21,512,769. <\/span><\/p>\n

CONFERENCE CALL<\/span><\/strong><\/p>\n

CEO Magnus Nilsson will present the report in a conference call at 2 p.m. CET on Wednesday, August 13, 2014. <\/span>Telephone: +44 (0) 1452 558567, enter code 67955875.<\/span><\/span><\/p>\n

\n

For further information please contact:
<\/span>
Christoffer Rosenblad, CFO, +46 31\u00a0788 21 59, christoffer.rosenblad@xvivoperfusion.com<\/a><\/span>
For further information on XVIVO Perfusion\u2019s business, please refer to the company\u2019s website, www.xvivoperfusion.com<\/a><\/span><\/p>\n

The information was submitted for publication on\u00a0August 13, 2014\u00a0at 8:30 a.m.<\/span><\/p>\n

This is a translation of the Swedish version of the press release. When in doubt, the Swedish wording prevails.<\/span><\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

SECOND QUARTER 2014 (APR \u2013 JUN) \u2022 Net sales in the quarter amounted to SEK 18.5 (15.8) million, corresponding to…<\/p>\n","protected":false},"template":"","class_list":["post-3167","mfn_news","type-mfn_news","status-publish","hentry","mfn-news-tag-mfn","mfn-news-tag-mfn-type-ir","mfn-news-tag-mfn-lang-en","mfn-news-tag-mfn-regulatory","mfn-news-tag-mfn-regulatory-vpml","mfn-news-tag-mfn-report","mfn-news-tag-mfn-report-interim","mfn-news-tag-mfn-report-interim-q2"],"acf":[],"yoast_head":"\nCONTINUED STRONG SALES GROWTH AND SEK 73 MILLION PRIVATE PLACEMENT - XVIVO<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.xvivogroup.com\/us\/pressreleases\/continued-strong-sales-growth-and-sek-73-million-private-placement\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"CONTINUED STRONG SALES GROWTH AND SEK 73 MILLION PRIVATE PLACEMENT - XVIVO\" \/>\n<meta property=\"og:description\" content=\"SECOND QUARTER 2014 (APR \u2013 JUN) \u2022 Net sales in the quarter amounted to SEK 18.5 (15.8) million, corresponding to...\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.xvivogroup.com\/us\/pressreleases\/continued-strong-sales-growth-and-sek-73-million-private-placement\/\" \/>\n<meta property=\"og:site_name\" content=\"United States\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.xvivogroup.com\\\/us\\\/pressreleases\\\/continued-strong-sales-growth-and-sek-73-million-private-placement\\\/\",\"url\":\"https:\\\/\\\/www.xvivogroup.com\\\/us\\\/pressreleases\\\/continued-strong-sales-growth-and-sek-73-million-private-placement\\\/\",\"name\":\"CONTINUED STRONG SALES GROWTH AND SEK 73 MILLION PRIVATE PLACEMENT - XVIVO\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.xvivogroup.com\\\/us\\\/#website\"},\"datePublished\":\"2014-08-13T06:29:00+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.xvivogroup.com\\\/us\\\/pressreleases\\\/continued-strong-sales-growth-and-sek-73-million-private-placement\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.xvivogroup.com\\\/us\\\/pressreleases\\\/continued-strong-sales-growth-and-sek-73-million-private-placement\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.xvivogroup.com\\\/us\\\/pressreleases\\\/continued-strong-sales-growth-and-sek-73-million-private-placement\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.xvivogroup.com\\\/us\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"CONTINUED STRONG SALES GROWTH AND SEK 73 MILLION PRIVATE PLACEMENT\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.xvivogroup.com\\\/us\\\/#website\",\"url\":\"https:\\\/\\\/www.xvivogroup.com\\\/us\\\/\",\"name\":\"United States\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.xvivogroup.com\\\/us\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"CONTINUED STRONG SALES GROWTH AND SEK 73 MILLION PRIVATE PLACEMENT - XVIVO","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.xvivogroup.com\/us\/pressreleases\/continued-strong-sales-growth-and-sek-73-million-private-placement\/","og_locale":"en_US","og_type":"article","og_title":"CONTINUED STRONG SALES GROWTH AND SEK 73 MILLION PRIVATE PLACEMENT - XVIVO","og_description":"SECOND QUARTER 2014 (APR \u2013 JUN) \u2022 Net sales in the quarter amounted to SEK 18.5 (15.8) million, corresponding to...","og_url":"https:\/\/www.xvivogroup.com\/us\/pressreleases\/continued-strong-sales-growth-and-sek-73-million-private-placement\/","og_site_name":"United States","twitter_card":"summary_large_image","twitter_misc":{"Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.xvivogroup.com\/us\/pressreleases\/continued-strong-sales-growth-and-sek-73-million-private-placement\/","url":"https:\/\/www.xvivogroup.com\/us\/pressreleases\/continued-strong-sales-growth-and-sek-73-million-private-placement\/","name":"CONTINUED STRONG SALES GROWTH AND SEK 73 MILLION PRIVATE PLACEMENT - XVIVO","isPartOf":{"@id":"https:\/\/www.xvivogroup.com\/us\/#website"},"datePublished":"2014-08-13T06:29:00+00:00","breadcrumb":{"@id":"https:\/\/www.xvivogroup.com\/us\/pressreleases\/continued-strong-sales-growth-and-sek-73-million-private-placement\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.xvivogroup.com\/us\/pressreleases\/continued-strong-sales-growth-and-sek-73-million-private-placement\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/www.xvivogroup.com\/us\/pressreleases\/continued-strong-sales-growth-and-sek-73-million-private-placement\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.xvivogroup.com\/us\/"},{"@type":"ListItem","position":2,"name":"CONTINUED STRONG SALES GROWTH AND SEK 73 MILLION PRIVATE PLACEMENT"}]},{"@type":"WebSite","@id":"https:\/\/www.xvivogroup.com\/us\/#website","url":"https:\/\/www.xvivogroup.com\/us\/","name":"United States","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.xvivogroup.com\/us\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"}]}},"_links":{"self":[{"href":"https:\/\/www.xvivogroup.com\/us\/wp-json\/wp\/v2\/mfn_news\/3167","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.xvivogroup.com\/us\/wp-json\/wp\/v2\/mfn_news"}],"about":[{"href":"https:\/\/www.xvivogroup.com\/us\/wp-json\/wp\/v2\/types\/mfn_news"}],"wp:attachment":[{"href":"https:\/\/www.xvivogroup.com\/us\/wp-json\/wp\/v2\/media?parent=3167"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}